Foundayo™ is a drug approved by the U.S. Food and Drug Administration (FDA) on April 1, 2026, for chronic weight management. It is prescribed for adults with obesity, or who are overweight (a BMI of 27 or higher) with at least one weight-related health condition such as high blood pressure, heart disease, or kidney disease.
Foundayo is a brand name for orforglipron, a small molecule GLP-1 receptor agonist manufactured by Eli Lilly. Unlike Lilly's other weight loss medication Zepbound, Foundayo is not a peptide — it's a small molecule drug, which means it's absorbed differently by the body and can be taken at any time of day without food or water restrictions.
Foundayo mimics glucagon-like peptide-1 (GLP-1), a gut hormone released when you eat that slows digestion and helps you feel full. Unlike GLP-1 injections, Foundayo is a once-daily pill you can take any time of day — with or without food. It can help adults with obesity or overweight lose an average of 11% of their body weight when used alongside diet and exercise.*
💉Regulates insulin
📊Balances blood sugar
🥗Reduces appetite
Foundayo is available as an oral tablet in six doses: 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg. It is the second GLP-1 pill approved by the FDA for obesity, following the approval of Novo Nordisk's Wegovy pill in December 2025. It was approved in just 50 days — the fastest approval of a new molecular entity since 2002 — under the FDA's Commissioner's National Priority Voucher program.
Foundayo™ vs. Other Oral GLP-1 Options
| Factor | Foundayo™ (orforglipron) | Oral Semaglutide (Rybelsus) |
|---|
| Drug class | Small molecule GLP-1 RA | Peptide GLP-1 RA |
| Manufacturer | Eli Lilly | Novo Nordisk |
| FDA approval for obesity | Yes (April 2026) | No (approved for T2D only) |
| Fasting required | No — any time of day | Yes — 30 min empty stomach |
| Food restrictions | None | Strict (no food/drink before) |
| Average weight loss | ~11% body weight* | ~5% body weight |
| Dosing | Once daily | Once daily |
Dosing Schedule
Like all GLP-1 treatments, Foundayo uses a gradual titration approach to minimize side effects:
| Phase | Duration | What Happens |
|---|
| Initiation | Weeks 1–4 | Low dose (0.8–2.5 mg); body adapts, mild appetite changes |
| Titration | Weeks 5–12 | Dose increases; noticeable appetite suppression and early weight loss |
| Therapeutic | Month 3+ | Full dose maintained; steady weight loss and metabolic improvements |
| Maintenance | Month 6+ | Maximum dose (up to 17.2 mg); weight stabilization or continued loss |
* Based on clinical trial data for orforglipron when used alongside diet and exercise in adults with obesity or overweight. Individual results may vary.
.svg){kind=logo}
